Indianapolis-based pharmaceutical company Eli Lilly $LLY sold $176 million of its new weight-loss drug Zepbound in just under a month, according to the company’s fourth-quarter earnings report released Tuesday. Zepbound, a GLP-1 weight loss drug similar to Ozempic and Wegovy (both made by Novo Nordisk), launched in December.
